@tamedoncol.bsky.socialGet ready for #ESMO26 by revisiting the evolving treatment landscape of #SCLC with this review published on #TAMO in 2025.
From current standards to DLL3-targeted therapies, #ADCs and emerging biomarkers.
#Lungcancer
🔗 buff.ly/B2U9VpQ
@Roya_Behrouzi @fblackhall
@tamedoncol.bsky.socialOnline on #TAMO
Lymphocyte recovery after breast RT may take years.
In 203 pts from the phase III CHN HYPOBREAST trial, HFRT was associated with less ≥G2 lymphopenia vs CFRT (6.5% vs 24.5%) and earlier recovery to baseline.
#BreastCancer #RadOnc
buff.ly/gW1OmN9
@tamedoncol.bsky.socialOn #TAMO in 2025
How can AR-targeted therapy move beyond resistance in #prostate cancer?
Emerging strategies (i.e. CYP11A1 inhibition/AR degraders/EZH2 inhibitors) are explored in this comprehensive review.
@alicebernardt
journals.sagepub.com/doi/10.1177/...
@globalvisibility.bsky.social@tamedoncol.bsky.socialOn #TAMO in 2025
🤰 Fertility preservation is a key component of care for young patients with #breast #cancer.
Interesting evidence in this RW cohort where 54% underwent cryopreservation.
More details here: journals.sagepub.com/doi/full/10.... @matteolambe
@theakarifoundation.bsky.social
@tamedoncol.bsky.socialOn #TAMO in 2025.
.
End-of-life care is crucial in pancreatic #cancer. In this French cohort, 41% of pts received high-intensity EOL care, while #palliativecare involvement was associated with lower care intensity.
.
👉 buff.ly/PyI4jy2
@tigertales.bsky.socialThe tale of tea’s secret origin and its connection to zen meditation. #tea #tamo #bodhidarhma #comic #myth
@dailybaltic.comPolice say Panevezys TAMO platform was breached and school threat sent #Panevėžys #police #TAMO
@tamedoncol.bsky.socialOn #TAMO in 2025
💊 🫁 🧬
Real-world evidence on selpercatinib in RET-rearranged #NSCLC is limited. In this updated analysis of LIBRETTO-321, selpercatinib showed durable responses, prolonged survival, and a good safety profile in Chinese patients.
journals.sagepub.com/doi/full/10....
@tamedoncol.bsky.socialAre T-cell engagers ready to reshape the #treatment of solid #tumors?
This review summarizes current evidence on their safety profile and AE management, key challenges in clinical practice.
journals.sagepub.com/doi/full/10....
#TAMO #oncology
@tamedoncol.bsky.socialOn #TAMO in 2025.
.
In a retrospective 20-center study, a depth of response ≥15% independently predicted longer PFS in pre-treated BRAFV600E #mCRC receiving encorafenib + cetuximab ± binimetinib.
Read more:
journals.sagepub.com/doi/full/10....
@Guv_onc @ChiaraCrem1 #colorectal #cancer